Eelco Fokkema

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

Eelco Fokkema, Bonne Biesma, Wolfgang Snoek et al. · British Journal of Cancer · 1998 · 188 citations

Medicine, Oncology, Pharmacology +13

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

Harry J.M. Groen, Eelco Fokkema, Bonne Biesma et al. · Journal of Clinical Oncology · 1999 · 114 citations

Medicine, Oncology, Pharmacology +14

Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study

Harry J.M. Groen, A.H.W. van der Leest, Eelco Fokkema et al. · Annals of Oncology · 2004 · 68 citations

Medicine, Oncology, Pharmacology +13

JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin

Eelco Fokkema, Harry J.M. Groen, Marco N. Helder et al. · Biochemical Pharmacology · 2002 · 64 citations

Medicine, Oncology, Toxicology +16

Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer

Eelco Fokkema, Harry J.M. Groen, Jean Bauer et al. · Journal of Clinical Oncology · 1999 · 51 citations

Pharmacy, Oncology, Pharmacology +17